ELCC 2018 | Therapy sequencing in the current NSCLC treatment landscape

Nicolas Girard

In this video, recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland, Nicolas Girard, MD, PhD, of Claude Bernard University, Lyon, France, discusses treatment sequencing for EGFR mutant non-small cell lung cancer (NSCLC). He speaks about the wide range of TKIs and immune checkpoint inhibitors available, and how new research and clinical understanding will illuminate the best way to use these therapies in relation to other treatments such as chemotherapy.

Share this video